YZYingqiao Zhu

Yingqiao Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yingqiao Zhu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Bao-Rong Chi

    Department of Cardiology, The First Hospital of Jilin University, Changchun, China

    1 shared publication
  • Changbin Yang

    Department of Radiation Oncology, The Tumor Hospital of Jilin Province, Changchun, Jilin 130012, P.R. China

    1 shared publication
  • Chunshu Jia

    The First Hospital of Jilin University, Changchun, China

    1 shared publication
  • Dirk M. Hermann

    Department of Neurology, University Hospital Essen, Essen, Germany

    1 shared publication
  • Dongxuan Wang

    Department of Ultrasound, First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China

    1 shared publication
  • Eric Metzen

    Department of Physiology, University of Duisburg-Essen, Essen, Germany

    1 shared publication

Latest Publications

  • Open Access

    Coexisting and possible primary extra-gastrointestinal stromal tumors of the pancreas and liver: A single case report

    by Lei Liu, Yingqiao Zhu, Dongxuan Wang, Changbin Yang, Qi Zhang, Xiukun Li, Yang Bai

    Gastrointestinal stromal tumors (GIST) are mesenchymal neoplasms of the gastrointestinal tract (GI) that are defined, in part, by the expression of CD117, a c-Kit proto-oncogene protein. GISTs emerge outside of the GI at a very low frequency, typically in a single organ or location. GISTs that occasionally emerge outside of the GI are classified as extra-gastrointestinal stromal tumors (EGIST). The present study reports an extremely rare case of EGIST detected in the pancreas and the liver. The pancreatic and liver tumors were 4.5×2.5 cm and 2.0×1.5 cm in size, respectively. Both tumors consisted of CD117-positive spindle cells with a similar mitotic rate of 1–2 per 50 high power fields. The pancreatic and the hepatic EGISTs were at a low risk of malignancy, and both tumors were proposed to be primary stromal tumors. To the best of our knowledge, this is the first report of likely primary EGIST identified in the pancreas and liver of the same patient.


  • Open Access

    Synergistic Antitumor Effects of Endostar in Combination with Oxaliplatin via Inhibition of HIF and CXCR4 in the Colorectal Cell Line SW1116

    by Fengyan Jin, Huifan Ji, Chunshu Jia, Ulf Brockmeier, Dirk M. Hermann, Eric Metzen, Yingqiao Zhu, Baorong Chi

    Combination treatment with endostar, a novel modified endostatin, and cytotoxic chemotherapies showed a survival benefit in Chinese clinical trials. However, the exact mechanism for this synergism remains unclear. In this study, we report for the first time that the chemokine receptor CXCR4 and the hypoxia-inducible transcription factors (HIF)-1α and HIF-2α are involved in these synergistic antitumor effects in human colorectal cancer SW1116 cells in vitro when endostar treatment is combined with the cytotoxic drug oxaliplatin. Under normoxia, we demonstrate that endostar and oxaliplatin treatments synergize to inhibit SW1116 cell proliferation, Matrigel adhesion and invasion by reduction of CXCR4 expression. Consistently, these antitumor abilities of endostar and oxaliplatin were markedly reduced by silencing of CXCR4 in SW1116 cells. Under low oxygen conditions (hypoxia, 1% oxygen), enhanced proliferation of SW1116 cells exposed to oxaliplatin was observed due to the emergence of drug resistance. Strikingly, endostar overcame oxaliplatin-resistance, most likely as a consequence of reduced HIF-2α and CXCR4 levels. CXCR4, is only dependent on HIF-2α, which promotes more aggressive phenotype and more significant for oxaliplatin resistance in SW1116 cells. Our data not only provide clues to aid understanding of the mechanism of the synergism of endostar and chemotherapy under either normoxia or hypoxia, but also suggests a new strategy of combination endostar and chemotherapy treatments which might potentiate therapeutic efficacies and/or counteract chemotherapy resistance.